159 related articles for article (PubMed ID: 27179912)
1. Beta blockers and cancer prognosis - The role of immortal time bias: A systematic review and meta-analysis.
Weberpals J; Jansen L; Carr PR; Hoffmeister M; Brenner H
Cancer Treat Rev; 2016 Jun; 47():1-11. PubMed ID: 27179912
[TBL] [Abstract][Full Text] [Related]
2. Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis.
Weberpals J; Jansen L; van Herk-Sukel MPP; Kuiper JG; Aarts MJ; Vissers PAJ; Brenner H
Eur J Epidemiol; 2017 Nov; 32(11):1019-1031. PubMed ID: 28864947
[TBL] [Abstract][Full Text] [Related]
3. β-Blocker use and mortality in cancer patients: systematic review and meta-analysis of observational studies.
Zhong S; Yu D; Zhang X; Chen X; Yang S; Tang J; Zhao J; Wang S
Eur J Cancer Prev; 2016 Sep; 25(5):440-8. PubMed ID: 26340056
[TBL] [Abstract][Full Text] [Related]
4. Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis.
Raimondi S; Botteri E; Munzone E; Cipolla C; Rotmensz N; DeCensi A; Gandini S
Int J Cancer; 2016 Jul; 139(1):212-9. PubMed ID: 26916107
[TBL] [Abstract][Full Text] [Related]
5. Common medications and survival in women with ovarian cancer: A systematic review and meta-analysis.
Majidi A; Na R; Dixon-Suen S; Jordan SJ; Webb PM
Gynecol Oncol; 2020 Jun; 157(3):678-685. PubMed ID: 32317171
[TBL] [Abstract][Full Text] [Related]
6. Post-Diagnostic Beta Blocker Use and Prognosis of Ovarian Cancer: A Systematic Review and Meta-Analysis of 11 Cohort Studies With 20,274 Patients.
Wen ZY; Gao S; Gong TT; Jiang YT; Zhang JY; Zhao YH; Wu QJ
Front Oncol; 2021; 11():665617. PubMed ID: 34221981
[TBL] [Abstract][Full Text] [Related]
7. Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies.
Yap A; Lopez-Olivo MA; Dubowitz J; Pratt G; Hiller J; Gottumukkala V; Sloan E; Riedel B; Schier R
Br J Anaesth; 2018 Jul; 121(1):45-57. PubMed ID: 29935594
[TBL] [Abstract][Full Text] [Related]
8. The influence of immortal time bias in observational studies examining associations of antifibrotic therapy with survival in idiopathic pulmonary fibrosis: A simulation study.
Zheng Q; Otahal P; Cox IA; de Graaff B; Campbell JA; Ahmad H; Walters EH; Palmer AJ
Front Med (Lausanne); 2023; 10():1157706. PubMed ID: 37113607
[TBL] [Abstract][Full Text] [Related]
9. Immortal Time Bias in National Cancer Database Studies.
Newman NB; Brett CL; Kluwe CA; Patel CG; Attia A; Osmundson EC; Kachnic LA
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):5-12. PubMed ID: 31404580
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of MMP Family Members Functions as Prognostic Biomarker for Breast Cancer Patients: A Systematic Review and Meta-Analysis.
Ren F; Tang R; Zhang X; Madushi WM; Luo D; Dang Y; Li Z; Wei K; Chen G
PLoS One; 2015; 10(8):e0135544. PubMed ID: 26270045
[TBL] [Abstract][Full Text] [Related]
11. Impact of beta blockers on survival outcomes in ovarian cancer: a nationwide population-based cohort study.
Baek MH; Kim DY; Kim SO; Kim YJ; Park YH
J Gynecol Oncol; 2018 Nov; 29(6):e82. PubMed ID: 30207092
[TBL] [Abstract][Full Text] [Related]
12. Effects of metformin on survival outcomes of pancreatic cancer patients with diabetes: A meta-analysis.
Xin W; Fang L; Fang Q; Zheng X; Huang P
Mol Clin Oncol; 2018 Mar; 8(3):483-488. PubMed ID: 29468063
[TBL] [Abstract][Full Text] [Related]
13. Pre- and post-diagnostic beta-blocker use and prognosis after colorectal cancer: Results from a population-based study.
Jansen L; Weberpals J; Kuiper JG; Vissers PAJ; Wolkewitz M; Hoffmeister M; Brenner H
Int J Cancer; 2017 Jul; 141(1):62-71. PubMed ID: 28370155
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women.
Botteri E; Munzone E; Rotmensz N; Cipolla C; De Giorgi V; Santillo B; Zanelotti A; Adamoli L; Colleoni M; Viale G; Goldhirsch A; Gandini S
Breast Cancer Res Treat; 2013 Aug; 140(3):567-75. PubMed ID: 23912960
[TBL] [Abstract][Full Text] [Related]
15. Is Beta-Blocker Use Beneficial in Breast Cancer? A Meta-Analysis.
Kim HY; Jung YJ; Lee SH; Jung HJ; Pak K
Oncology; 2017; 92(5):264-268. PubMed ID: 28132057
[TBL] [Abstract][Full Text] [Related]
16. β-Adrenergic Receptors : New Target in Breast Cancer.
Wang T; Li Y; Lu HL; Meng QW; Cai L; Chen XS
Asian Pac J Cancer Prev; 2015; 16(18):8031-9. PubMed ID: 26745035
[TBL] [Abstract][Full Text] [Related]
17. Stage-specific associations between beta blocker use and prognosis after colorectal cancer.
Jansen L; Hoffmeister M; Arndt V; Chang-Claude J; Brenner H
Cancer; 2014 Apr; 120(8):1178-86. PubMed ID: 24415516
[TBL] [Abstract][Full Text] [Related]
18. Brief Communication on the Impact of β-blockers on Outcomes in Patients Receiving Cancer Immunotherapy.
Kennedy OJ; Neary MT
J Immunother; 2022 Sep; 45(7):303-306. PubMed ID: 35947120
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of the effects of beta blocker on survival time in cancer patients.
Choi CH; Song T; Kim TH; Choi JK; Park JY; Yoon A; Lee YY; Kim TJ; Bae DS; Lee JW; Kim BG
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1179-88. PubMed ID: 24671228
[TBL] [Abstract][Full Text] [Related]
20. Effect of beta-blockers on survival of lung cancer patients: a systematic review and meta-analysis.
Coelho M; Squizzato A; Cassina N; Marino F; Ribeiro LV; Cosentino M
Eur J Cancer Prev; 2020 Jul; 29(4):306-314. PubMed ID: 31609808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
